Deep Genomics vs Neuralink
Side-by-side comparison of AI visibility scores, market position, and capabilities
Deep Genomics uses AI to discover and design RNA-based therapies for genetic diseases; its AI Workbench platform decodes RNA biology at scale; raised over $180M in funding including a $40M Series C extension in 2022;
About
Deep Genomics is a biopharmaceutical company founded in 2015 by Brendan Frey and headquartered in Toronto, Ontario, Canada. The company applies artificial intelligence to the challenge of RNA biology — developing a proprietary AI Workbench platform that can predict how genetic variants affect RNA splicing, processing, and gene expression. This computational capability allows Deep Genomics to identify disease-causing mutations that alter RNA function and to design antisense oligonucleotide (ASO) and other RNA-based therapies that correct those molecular defects — a process that traditionally requires years of manual biological experimentation.
Pioneer of implantable BCIs with 12+ active human patients as of Sep 2025; raised $650M Series E in Apr 2026 led by ARK Invest and Sequoia at a ~$14.9B valuation; mass production underway.
About
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with paralysis to control digital devices directly with their thoughts. The company's first commercial product, the N1 implant, is a coin-sized device containing 1,024 electrodes that is surgically placed in the motor cortex. As of September 2025, twelve patients worldwide had received the N1 implant and were actively using it to control computers, smartphones, and robotic arms with neural signals alone.
AI Visibility Head-to-Head
Key Details
Also Compare
Deep Genomics vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.